Annotation Detail
Information
- Associated Genes
- MET
- Associated Variants
-
MET MUTATION
MET MUTATION - Associated Disease
- papillary renal cell carcinoma
- Source Database
- CIViC Evidence
- Description
- In a retrospective analysis of 74 patients with papillary renal cell carcinoma, treated with foretinib, MET germline mutation was associated with improved response rate. A response was observed in 5 of 10 (50%) vs. 5 of 57 (8.8%) patients with and without germline MET mutations, respectively.
- Variant Origin
- germline
- Variant Origin
- Rare Germline
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/796
- Gene URL
- https://civic.genome.wustl.edu/links/genes/52
- Variant URL
- https://civic.genome.wustl.edu/links/variants/323
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Papillary Renal Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Foretinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23213094
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Foretinib | Sensitivity | true |